Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2447190rdf:typepubmed:Citationlld:pubmed
pubmed-article:2447190lifeskim:mentionsumls-concept:C0007600lld:lifeskim
pubmed-article:2447190lifeskim:mentionsumls-concept:C0010453lld:lifeskim
pubmed-article:2447190lifeskim:mentionsumls-concept:C0022567lld:lifeskim
pubmed-article:2447190lifeskim:mentionsumls-concept:C0229664lld:lifeskim
pubmed-article:2447190lifeskim:mentionsumls-concept:C0007137lld:lifeskim
pubmed-article:2447190lifeskim:mentionsumls-concept:C0567416lld:lifeskim
pubmed-article:2447190lifeskim:mentionsumls-concept:C0039194lld:lifeskim
pubmed-article:2447190lifeskim:mentionsumls-concept:C0028778lld:lifeskim
pubmed-article:2447190lifeskim:mentionsumls-concept:C0221912lld:lifeskim
pubmed-article:2447190lifeskim:mentionsumls-concept:C1522642lld:lifeskim
pubmed-article:2447190lifeskim:mentionsumls-concept:C0023517lld:lifeskim
pubmed-article:2447190lifeskim:mentionsumls-concept:C0205282lld:lifeskim
pubmed-article:2447190lifeskim:mentionsumls-concept:C1518174lld:lifeskim
pubmed-article:2447190lifeskim:mentionsumls-concept:C0003241lld:lifeskim
pubmed-article:2447190lifeskim:mentionsumls-concept:C0021740lld:lifeskim
pubmed-article:2447190lifeskim:mentionsumls-concept:C0079717lld:lifeskim
pubmed-article:2447190lifeskim:mentionsumls-concept:C0442805lld:lifeskim
pubmed-article:2447190lifeskim:mentionsumls-concept:C1167622lld:lifeskim
pubmed-article:2447190lifeskim:mentionsumls-concept:C0332206lld:lifeskim
pubmed-article:2447190pubmed:issue1lld:pubmed
pubmed-article:2447190pubmed:dateCreated1988-2-4lld:pubmed
pubmed-article:2447190pubmed:abstractTextBecause keratinocytes (KCs) express HLA-DR in a wide variety of skin diseases in which mononuclear leukocytes are observed in close apposition to KCs (i.e., graft-versus-host disease), and since gamma interferon (IFN-gamma) induces HLA-DR expression on KCs, we asked whether IFN-gamma treatment of KCs would influence the adherence of mononuclear leukocytes. When allogeneic peripheral blood mononuclear leukocytes (PBML) and a Leu-3+ T cell clone were coincubated with IFN-gamma-treated KCs (300 U/ml, 3 days), there was a marked increase in binding compared with nontreated KCs. Similar binding results were obtained using a cutaneous squamous carcinoma cell line (SCL-1) after IFN-gamma treatment. The IFN effect was relatively specific for IFN-gamma, as neither IFN-alpha nor -beta had any effect. Tumor necrosis factor exposure (500 U/ml, 3 days) increased the binding of the Leu-3+ T cell clone to both KCs and SCL-1 cells. Neutrophils displayed a less marked (but statistically significant) increase in binding to IFN-gamma-treated KCs. Using the Leu-3+ cell clone and SCL-1 cells, detailed kinetic analysis of the effect of IFN-gamma on binding was performed. The increased adherence between the cells began to appear after only 7 hours of treatment with r-IFN-gamma (300 U/ml) and reached a plateau at 48 hours, with significantly enhanced binding continuing for at least 48 hours after removal of IFN-gamma. The mechanism of binding was explored by preincubation of the PBML/Leu-3+ T cells with anti-LFA-1 (lymphocyte function-associated antigen) antibody (0.6-6.0 micrograms/ml), which totally inhibited the binding with no effect by anti-LFA-2 or -3 or class I or II antibodies despite documented binding of these antibodies to the cells. These results suggest that, after exposure to IFN-gamma, the ability of KCs to bind mononuclear leukocytes is strongly enhanced, and this adherence may be important in leukocyte trafficking in the skin as well as contributing to altered KC-leukocyte interaction, which may be of fundamental importance in a variety of skin disease.lld:pubmed
pubmed-article:2447190pubmed:languageenglld:pubmed
pubmed-article:2447190pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2447190pubmed:citationSubsetIMlld:pubmed
pubmed-article:2447190pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2447190pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2447190pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2447190pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2447190pubmed:statusMEDLINElld:pubmed
pubmed-article:2447190pubmed:monthJanlld:pubmed
pubmed-article:2447190pubmed:issn0022-202Xlld:pubmed
pubmed-article:2447190pubmed:authorpubmed-author:ButcherE CEClld:pubmed
pubmed-article:2447190pubmed:authorpubmed-author:ClaybergerCClld:pubmed
pubmed-article:2447190pubmed:authorpubmed-author:KrenskyA MAMlld:pubmed
pubmed-article:2447190pubmed:authorpubmed-author:NickoloffB...lld:pubmed
pubmed-article:2447190pubmed:authorpubmed-author:LewinsohnD...lld:pubmed
pubmed-article:2447190pubmed:issnTypePrintlld:pubmed
pubmed-article:2447190pubmed:volume90lld:pubmed
pubmed-article:2447190pubmed:ownerNLMlld:pubmed
pubmed-article:2447190pubmed:authorsCompleteYlld:pubmed
pubmed-article:2447190pubmed:pagination17-22lld:pubmed
pubmed-article:2447190pubmed:dateRevised2008-11-21lld:pubmed
pubmed-article:2447190pubmed:meshHeadingpubmed-meshheading:2447190-...lld:pubmed
pubmed-article:2447190pubmed:meshHeadingpubmed-meshheading:2447190-...lld:pubmed
pubmed-article:2447190pubmed:meshHeadingpubmed-meshheading:2447190-...lld:pubmed
pubmed-article:2447190pubmed:meshHeadingpubmed-meshheading:2447190-...lld:pubmed
pubmed-article:2447190pubmed:meshHeadingpubmed-meshheading:2447190-...lld:pubmed
pubmed-article:2447190pubmed:meshHeadingpubmed-meshheading:2447190-...lld:pubmed
pubmed-article:2447190pubmed:meshHeadingpubmed-meshheading:2447190-...lld:pubmed
pubmed-article:2447190pubmed:meshHeadingpubmed-meshheading:2447190-...lld:pubmed
pubmed-article:2447190pubmed:meshHeadingpubmed-meshheading:2447190-...lld:pubmed
pubmed-article:2447190pubmed:meshHeadingpubmed-meshheading:2447190-...lld:pubmed
pubmed-article:2447190pubmed:meshHeadingpubmed-meshheading:2447190-...lld:pubmed
pubmed-article:2447190pubmed:meshHeadingpubmed-meshheading:2447190-...lld:pubmed
pubmed-article:2447190pubmed:meshHeadingpubmed-meshheading:2447190-...lld:pubmed
pubmed-article:2447190pubmed:meshHeadingpubmed-meshheading:2447190-...lld:pubmed
pubmed-article:2447190pubmed:meshHeadingpubmed-meshheading:2447190-...lld:pubmed
pubmed-article:2447190pubmed:year1988lld:pubmed
pubmed-article:2447190pubmed:articleTitleRecombinant gamma interferon increases the binding of peripheral blood mononuclear leukocytes and a Leu-3+ T lymphocyte clone to cultured keratinocytes and to a malignant cutaneous squamous carcinoma cell line that is blocked by antibody against the LFA-1 molecule.lld:pubmed
pubmed-article:2447190pubmed:affiliationDepartment of Pathology, Stanford University School of Medicine, California.lld:pubmed
pubmed-article:2447190pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2447190lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2447190lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2447190lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2447190lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2447190lld:pubmed